OSE.PA AI Price Prediction

Track OSE.PA's AI-powered predictions, market trends, and investment insights.

OSE.PA Sentiment OSE.PA StockTwits OSE.PA Reddit

Mock Tradesimulated, no real money

You don't hold OSE.PA in your mock portfolio yet.

OSE.PA AI Price Prediction

Track OSE.PA's AI-powered predictions, market trends, and investment insights.

OSE.PA Sentiment OSE.PA StockTwits OSE.PA Reddit

Evidence Stack

What Changed?

Key moves vs recent baseline (last day / last week)

Price (1d)-11.2%

Price (7d)+5.3%

Volume vs avg1.5x

Volatility vs normal1.7x

Why Now?

Plain-English summary of the biggest drivers (informational)

Risk Flags

Potential risk factors to review

High volatility regime

ATR 1.7x normal — larger swings expected

Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.

Invalidation Signals

Reassess your thesis if any of these occur:

Price breaks below ~€3.46 (recent support level)

Upgrade to see the full Evidence Stack

What Changed, Why Now, and Risk Flags — available on the Investor plan and above

Get Started

OSE.PA AI Stock Analysis

Financial Performance

bearish

The company is currently loss-making, as reflected in its negative EPS of -1.69 and a negative PE ratio of -3.04. This indicates the business is not yet generating positive net income and likely remains in an investment or R&D-heavy phase. From a pure fundamentals standpoint, profitability is a clear weakness and a key risk for equity holders.

Negative EPS of -1.69 signals ongoing net losses and lack of current earnings power.
A PE ratio of -3.04 confirms that the stock is not supported by positive earnings and that valuation is based on expectations of future success rather than present profitability.
Absent evidence of improving margins or a clear path to break-even, the financial profile is fundamentally weak and sensitive to financing and execution risk.

Stock Price & Technicals

bullish

The stock has risen 59.1% over the last month and now trades modestly above its 200-day moving average at €5.14 versus €4.99, indicating a strong short-term momentum shift and a potential transition into an uptrend. Trading above the 200-day moving average is generally interpreted as a positive long-term technical signal. Without an explicit RSI value, the magnitude and speed of the recent move suggest elevated momentum, which can support further upside but also raises the risk of near-term volatility or pullbacks.

Price at €5.14 is above the 200-day moving average of €4.99, a constructive long-term technical sign that often aligns with emerging or established uptrends.
A 59.1% gain in one month reflects very strong positive momentum, likely driven by news flow, sentiment shifts, or expectations around the company’s pipeline or strategic developments.
The strength and speed of the rally suggest momentum is currently favorable, but also imply higher short-term risk of profit-taking if no new positive catalysts emerge.

Alternative Data Signals

neutral

Alternative data for OSE Immunotherapeutics SA show a relatively small but stable digital footprint, with modest web traffic and a niche social media presence. The absence of job openings and flat follower growth on Twitter/X point to limited current expansion or marketing push, though LinkedIn followers are comparatively higher, suggesting some professional and industry awareness. Overall, these signals neither strongly confirm nor contradict the recent sharp move in the share price.

Estimated web traffic of 3,252 visitors per month is low, indicating limited broad retail or customer engagement, which is typical for small-cap biotech but does not signal surging external interest.
Zero job openings and 0.0% month-over-month change suggest no visible hiring acceleration, which may imply a stable but not rapidly scaling operational footprint.
Social media presence is modest—2,108 Twitter/X followers with 0% growth over 90 days versus a more substantial 20,854 LinkedIn followers—indicating better recognition within professional and industry circles than among the general public, but without clear recent momentum.

Conclusion

neutral

OSE Immunotherapeutics SA presents a mixed picture: technically, the stock looks strong after a sharp recent rally and a move above its 200-day moving average, but the underlying financials remain loss-making with negative earnings. Alternative data show a stable but not rapidly expanding digital and hiring footprint, offering limited confirmation of a fundamental inflection. Overall, the setup appears neutral: recent price action is bullish, yet it rests on a fragile earnings base and modest external traction, making the outlook highly dependent on future clinical, regulatory, or partnership catalysts.

Stock price momentum and technicals are currently bullish, but they are not yet backed by improving profitability metrics.
Alternative data and lack of visible operational scaling temper the enthusiasm from the recent rally, leading to an overall neutral stance pending clearer evidence of sustainable business progress.

AI Score

Hold

Alternative4

Fundamental9

Technical4

Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.

Mock Tradesimulated, no real money

You don't hold OSE.PA in your mock portfolio yet.